Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Bristol-Myers Squibb clinical trials

Also known as BMS.

The registry lists 2,184 studies whose lead sponsor is Bristol-Myers Squibb or one of 14 companies grouped under it. 162 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Keep track of what changes. Save the Bristol-Myers Squibb studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Status

Completed: 1,577
Terminated: 237
Recruiting: 134
Active, not recruiting: 101
Withdrawn: 71
No longer available: 26

Phase

Phase 1: 871
Phase 2: 611
Phase 3: 397
Phase 4: 59
Early Phase 1: 3

Where

United States: 1,567
Spain: 541
France: 539
Canada: 539
Italy: 497
Germany: 479

Focus areas

Conditions Bristol-Myers Squibb leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 72 areas

Liver Diseases25 Colorectal Neoplasms24 Heart Failure24 Leukemia, Lymphocytic, Chronic, B-Cell24 Alzheimer Disease23 Colitis, Ulcerative22 Infections22 Lupus Erythematosus, Systemic22 Neoplasm Metastasis22 Schizophrenia22 Pancreatic Neoplasms21 Lymphoma, B-Cell20 Lymphoma, Large B-Cell, Diffuse20 Small Cell Lung Carcinoma20 Carcinoma, Hepatocellular19 Hematologic Neoplasms19 Diabetes Mellitus, Type 218 Lymphoma, Follicular18 Multiple Sclerosis18 Diabetes Mellitus17 Crohn Disease16 Glioblastoma16 Primary Myelofibrosis15 Renal Insufficiency15 Squamous Cell Carcinoma of Head and Neck15 Ulcer15 Anemia14 Precursor Cell Lymphoblastic Leukemia-Lymphoma14 Stomach Neoplasms14 Sclerosis13 Adenocarcinoma12 Arthritis, Psoriatic12 Carcinoma, Transitional Cell12 Embolism12 Hodgkin Disease12 Kidney Neoplasms12 Lymphoma, Mantle-Cell12 Thromboembolism12 beta-Thalassemia11 Pulmonary Fibrosis11 Cardiomyopathies10 Head and Neck Neoplasms10 Lymphoma, T-Cell10 Non-alcoholic Fatty Liver Disease10 Philadelphia Chromosome10 Pulmonary Embolism10 Urinary Bladder Neoplasms10 Venous Thromboembolism10

Studies

Recruiting first, then most recently updated. Showing 50 of 2,184. Browse all 2,184 →

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Phase 3
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingNCT06090539Phase 1/2
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRecruitingNCT06951698Phase 3
A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisRecruitingNCT07412704Phase 1/2
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingNCT07063745Phase 2/3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)RecruitingNCT07361510Phase 3
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingNCT07291076Phase 1/2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruitingNCT07221357Phase 2/3
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingNCT07293351Phase 1/2
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07680764Phase 2
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT06697197Phase 1/2
A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult ParticipantsNot yet recruitingNCT07887763Phase 1
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisRecruitingNCT05076175Phase 2/3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RecruitingNCT06951711Phase 3
RYZ711 Diagnostic Platform StudyNot yet recruitingNCT07862582Phase 1/2
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingNCT07221877Phase 4
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingNCT06126224Phase 3
Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingNCT05980949Phase 3
Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingNCT06937229Phase 3
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersRecruitingNCT07681076Phase 4
Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingNCT07011732Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingNCT07424404Phase 3
Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb
A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 1
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Phase 2/3
Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted before Mirati Therapeutics Inc. became part of Bristol-Myers Squibb
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCRecruitingNCT07671092Early Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingNCT07204418Phase 1
Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingNCT06646276Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Phase 3
Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb
Imaging Study in Metastatic Clear Cell RCC.RecruitingNCT07671417Early Phase 1
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingNCT07116967Phase 3
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)Not yet recruitingNCT07871214Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2
Sponsor listed in the registry: Mirati Therapeutics Inc. · First submitted after Mirati Therapeutics Inc. became part of Bristol-Myers Squibb
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingNCT07100080Phase 2/3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingNCT06976203Phase 3
Asia Myelodysplastic Syndrome (MDS) RegistryRecruitingNCT07355478
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingNCT07680790Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingNCT07011745Phase 3
A Phase 1 Study of Navlimetostat Tablet FormulationsRecruitingNCT07544628Phase 1
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06297226Phase 2
Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseRecruitingNCT06808984Phase 2
Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2
Sponsor listed in the registry: RayzeBio, Inc. · First submitted after RayzeBio, Inc. became part of Bristol-Myers Squibb
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT06997029Phase 1
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingNCT06976216Phase 3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisRecruitingNCT06869551Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingNCT07288567Phase 3
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingNCT07492680Phase 2
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy ParticipantsRecruitingNCT07800897Phase 1
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityRecruitingNCT06782490Phase 2
Sponsor listed in the registry: Celgene · First submitted after Celgene became part of Bristol-Myers Squibb
A Study to Assess Deucravacitinib Safety in PregnancyRecruitingNCT07017699
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisRecruitingNCT07171983Phase 1